12:00 AM
 | 
Dec 03, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/30 cls
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Needham Alan Carr Upgrade Buy (from hold) 134% $5.20
Carr also set a $9 target after Acadia reported that once-daily 40 mg oral pimavanserin as an adjunct to stable doses of existing anti-Parkinson's therapy met the primary endpoint in the Phase III ACP-103-020 trial to treat Parkinson's disease psychosis (PDP) (see B24). Acadia is planning an identical Phase III trial, but did not provide a timeline. Pimavanserin is a small molecule serotonin (5-HT2A) receptor inverse agonist.
Bruker Corp. (NASDAQ:BRKR) Goldman Sachs Isaac Ro Upgrade Buy (from neutral) 0% $14.60
Ro raised his target to $19 from...

Read the full 783 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >